耐久性双心室辅助装置的多中心应用经验
该多中心回顾性研究分析了2011至2017年间46例接受耐久性双心室辅助装置(BiVAD)患者的特征与结局。患者病情危重,手术死亡率为33%,右心室辅助装置(RVAD)血栓发生率为37%。同期植入BiVAD与分期植入相比,重症监护室停留时间更短且出院时仍带BiVAD支持的比例更高,但1年生存率差异无统计学意义。
要点
- 耐久性BiVAD患者手术死亡率高(33%),RVAD血栓发生率达37%。
- 同期BiVAD植入较分期植入ICU停留更短(12天 vs 42天,p=0.035)。
- 同期植入者出院时带BiVAD支持比例更高(61% vs 27%,p=0.04)。
核心结论
- 接受耐久性BiVAD的患者为危重双心室衰竭人群,手术死亡率和RVAD血栓发生率均较高。
- 在有经验的中心,同期BiVAD植入的1年生存率与其他 contemporary 耐久性双心室支持策略相当。
研究设计与样本
- 多中心回顾性研究,收集美国植入BiVAD≥6例的中心数据。
- 比较同期(同一次手术)与分期植入HVAD作为BiVAD的患者特征与结局。
- 2011至2017年共纳入46例接受耐久性BiVAD的患者。
主要发现
- 患者中位年龄46岁(IQR 19-67岁),非缺血性心肌病占80%,移植前过渡占83%。
- INTERMACS Profile 1或2占92%,使用临时循环支持者占37%。
- 右心房压19 mmHg(IQR 14-23 mmHg),心脏指数1.6 L/min/m²(IQR 1.2-2.1 L/min/m²)。
- 手术死亡率为33%,RVAD血栓形成发生于17例(37%)。
- 同期BiVAD植入31例(67%),分期植入15例(33%);同期组ICU停留12天(IQR 7-23天)vs 分期组42天(IQR 28-48天,p=0.035)。
临床怎么用
- 在经验丰富的中心,对于需要耐久性双心室支持的危重患者,可考虑同期植入BiVAD以缩短ICU停留并提高出院时带装置支持的比例。
- 需警惕BiVAD术后高手术死亡率和RVAD血栓风险,加强围术期管理。
局限性
- 回顾性研究,样本量较小(46例),仅纳入植入量≥6例的中心,可能存在选择偏倚。
- 同期与分期植入组间1年生存率差异无统计学意义(p=0.11),需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe right ventricular failure necessitating a right ventricular assist device (RVAD) complicates 6% to 11% of left ventricular assist device (LVAD) implants. Patient outcomes for those receiving durable continuous-flow VADs in a biventricular configuration (i.e., BiVAD) have been reported in limited case series. METHODS: Data from United States centers with ≥ 6 BiVAD implants were collected. Characteristics and outcomes of patients receiving contemporaneous (i.e., same surgery) vs staged implantation of the HVAD as a BiVAD were compared. RESULTS: From 2011 to 2017, 46 patients received durable BiVADs and had the following characteristics: median age, 46 years (interquartile range [IQR], 19-67 years), non-ischemic cardiomyopathy (80%), bridge to transplant (83%), Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 or 2 (92%), use of temporary circulatory support (37%), right atrial pressure 19 mm Hg (IQR, 14-23 mm Hg), and cardiac index of 1.6 liters/min/m2 (IQR, 1.2-2.1 liters/min/m2). Operative mortality was 33%. Equal numbers of patients received a right atrial or right ventricular implant. Contemporaneous BiVAD implantation occurred in 31 patients (67%), and compared with 15 patients (33%) with staged implants, these patients had a shorter intensive care unit length of stay of 12 days (IQR, 7-23 days) vs 42 days (IQR, 28-48 days, p = 0.035) and were more likely to be discharged from the hospital on BiVAD support (61% vs 27%, p = 0.04). RVAD thrombosis developed in 17 patients (37%). Patients with contemporaneous BiVAD implants had a 1-year survival of 74% compared with 40% in staged BiVAD patients (p = 0.11). CONCLUSIONS: Patients receiving durable BiVADs represent a critically ill patient population with severe biventricular failure who have high operative mortality and RVAD thrombosis rates. The 1-year survival for patients receiving contemporaneous BiVADs in experienced centers mirrors other contemporary durable biventricular support strategies.
引用
- Shah P, Ha R, Singh R, et al. Multicenter experience with durable biventricular assist devices. J Heart Lung Transplant. 2018. PMID: 30173824. doi:10.1016/j.healun.2018.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。